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Abstract
Background. Simultaneous pancreas–kidney (SPK)
transplantation has become the therapy of choice for
type 1 diabetic patients with end-stage renal disease.
The current analysis examined the impact of human
leukocyte antigen (HLA) matching on graft outcome
following SPK transplantation. The study population
was obtained from patients enrolled in the Euro-SPK
001 study.
Methods. The effect of HLA matching on graft
function and survival was assessed in 180 SPK reci-
pients in whom complete donor–recipient HLA data
were available. A group of 45 patients with 0–3 HLA
mismatches (MM) was compared with a group of
135 patients with 4–6 MM.
Results. There were no differences in 3-year kidney,
pancreas or patient survival between the 0–3 and
4–6 MM groups. Biological parameters of kidney and
pancreas graft function were similar in both groups.
Signiﬁcantly more patients with 0–3 MM (66%)
were rejection-free at 3 years than was the case among
those with 4–6 MM (41%; P¼ 0.003). The relative risk
of acute rejection was 2.6 times higher among patients
with 4–6 MM than among those with 0–3 MM.
Conclusions. There was no evidence that HLA match-
ing was associated with improved kidney or pancreas
survival. However, a higher rate of acute rejection was
observed with poor HLA match, which may impact
long-term survival.
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Introduction
Simultaneous pancreas–kidney (SPK) transplanta-
tion is the only treatment that can consistently
establish, on a large scale, freedom from dialysis
and an insulin-independent, euglycaemic state in
uraemic patients with type 1 insulin-dependent
diabetes mellitus [1]. The current success with this
procedure is reﬂected in its 1-year patient survival
rates of 95% and 1-year pancreatic graft sur-
vival rates in excess of 80% [2]. These excellent
survival rates are the result of improved donor
and recipient selection criteria, reﬁned surgical tech-
niques, better immunosuppressive protocols and
improved pre- and post-operative care [3–5].
The major histocompatibility system [human
leukocyte antigen (HLA) in man] has several func-
tions, including graft immunogenicity and host
response, disease susceptibility and cell co-operation
in immune responses. Registry data from both the
Collaborative Transplant Study and United Network
for Organ Sharing (UNOS) have demonstrated a
strong positive effect of HLA matching on the
outcome of kidney transplantation [6,7]. In pancreas
transplantation, however, the question of HLA
matching is confounded by the hypothesis that
the outcome may be worse in patients receiving a
DR-identical graft, since certain DR antigens are
associated with susceptibility to diabetes and also
because autoantigen recognition is undertaken in a
major histocompatibility complex (MHC)-restricted
fashion [8].
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The present analysis of the Euro-SPK 001 study was
undertaken to evaluate the potential effect of good
HLAmatching on the outcome of SPK transplantation
using modern immunosuppressive regimens based on
tacrolimus or cyclosporin microemulsion (ME).
Patients and methods
Study design
The overall objectives, methods and design of the Euro-SPK
001 study have been described in full previously [9] and
also elsewhere in this supplement (Saudek F et al.). A brief
synopsis is given below.
A total of 205 SPK transplant patients with end-stage,
C-peptide-negative, type 1 diabetic nephropathy were
recruited into the study from 10 centres in Europe
and one centre in Israel. All patients received quadruple
immunosuppressive therapy based on either tacrolimus
(n¼ 103) or cyclosporin-ME (n¼ 102), given with mycophe-
nolate mofetil (MMF), corticosteroids and antibody induc-
tion therapy (rabbit anti-thymocyte globulin). The initial
oral daily dose of tacrolimus was 0.2mg/kg, with subsequent
doses adjusted to target whole-blood trough levels in
the range 8–15 ng/ml by day 5 post-transplant. The recom-
mended initial oral daily dose of cyclosporin-ME was
7mg/kg, adjusted to target whole-blood trough levels
of 150–250 ng/ml by day 5. Corticosteroid therapy was
progressively withdrawn from all patients between 3 and
6 months post-transplantation.
HLA typing
HLA typing was undertaken individually at each centre.
Only broad antigens were taken into account for the donor–
recipient HLA matching. The three centres that had
speciﬁc HLA matching criteria accepted grafts from
donors with at least one HLA-DR match and one HLA-A
and/or HLA-B match (15 patients). None of the other
centres had an HLA matching policy.
Diagnosis of rejection and graft failure
In the majority of cases, rejection was diagnosed on the
basis of a renal transplant biopsy, although a diagnosis
of acute rejection was occasionally obtained empirically by
response to anti-rejection treatment in the absence of biopsy.
Renal graft failure was deﬁned as a permanent return to
haemodialysis, and pancreatic graft failure was deﬁned as
a permanent return to insulin therapy. Death with a
functioning graft was included as graft failure.
Statistical analysis
Statistical analyses were undertaken using the STATISTICA
software package (StatSoft, Tulsa, USA). The 2 and Fisher’s
exact tests were used to compare categorical variables.
The Mann–Whitney U-test was used for continuous vari-
ables. Survival rates and time-dependent variable rates
were estimated using the Kaplan–Meier method and were
compared using the log-rank test. Exploratory analyses
were undertaken using Cox multivariate regression analyses.
P<0.05 was considered to be statistically signiﬁcant. Mean
values are expressed with SDs.
Results
Analysis of HLA matching
HLA typing was available for 181 donors (88.3%)
and 184 recipients (89.8%). Complete HLA data for
both donor and recipient were available for 180
(87.8%) transplants (90 in each treatment group).
As shown in Table 1, both treatment arms were
comparable with respect to HLA matching, with
no statistically signiﬁcant differences between the
tacrolimus and cyclosporin-ME groups with regards to
class I, class II and combined class I and II matching
data.
Because of their similar size and HLA-matching
distribution, data from the tacrolimus and cyclosporin-
ME groups were pooled for further analysis.
The inﬂuence of HLA matching was studied by
comparing outcomes in patients with 0–3 HLA
mismatches (MM) (n¼ 45) and 4–6 MM (n¼ 135).
As shown in Table 2, the demographic data were
similar in the two MM groups, except for signiﬁcant
differences in donor age, higher in the 0–3 MM group
than in the 4–6 MM group (31.8 vs 28.5 years,
respectively; P¼ 0.046), and kidney ischaemic time,
which was longer in the 0–3 MM group (13 h and
13min vs 11 h and 36min; P¼ 0.047).
Table 1. Number of HLA mismatches in 180 recipients of SPK
transplants
No. (%) of patients
Tacrolimus
(n¼ 90)
Cyclosporin-ME
(n¼ 90)
Total
(n¼ 180)
Class I
A 0–1 60 (67) 55 (61) 115 (64)
A 2 30 (33) 35 (39) 65 (36)
B 0–1 34 (38) 40 (44) 74 (41)
B 2 56 (62) 50 (56) 106 (59)
AB 0–2 29 (32) 31 (34) 60 (33)
AB 3–4 61 (68) 59 (66) 120 (67)
Class II
DR 0 7 (8) 8 (9) 15 (8)
DR 0–1 51 (57) 48 (53) 99 (55)
DR 2 39 (43) 42 (47) 81 (45)
Class I and II
ABDR 0 0 1 (1) 1 (<1)
ABDR 1 1 (1) 3 (3) 4 (2)
ABDR 2 4 (4) 3 (3) 7 (4)
ABDR 3 19 (21) 14 (16) 33 (18)
ABDR 4 31 (34) 36 (40) 67 (37)
ABDR 5 26 (29) 23 (26) 49 (27)
ABDR 6 9 (10) 10 (11) 19 (11)
HLA¼ human leukocyte antigen; SPK¼ simultaneous pancreas–
kidney; cyclosporin-ME¼ cyclosporin microemulsion.
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Graft and patient survival
Details of graft and patient survival are summarized
in Table 3. Overall pancreas survival and kidney
survival were 82.9 and 93.7%, respectively, at 1 year
post-transplant, 79.5 and 92.7% at 2 years, and 79.0
and 91.2% at 3 years. No differences in actuarial
survival rates between the two MM groups were
seen for either pancreatic (P¼ 0.29) or kidney graft
survival (P¼ 0.65). Likewise, there were no signiﬁ-
cant differences between the two groups in terms
of actuarial patient survival rates (P¼ 0.62). Overall
patient survival was 97.6% at 1 year, 96.6% at
2 years and 96.1% at 3 years post-transplant.
Corticosteroid withdrawal
Corticosteroid withdrawal at month 6 and years 1,
2 and 3 post-transplant was achieved in nine, 17, 18
and 18 patients, respectively, in the 0–3 MM group
and in 23, 45, 64 and 66 patients in the 4–6 MM group.
No statistically signiﬁcant difference in the actuarial
rate of corticosteroid withdrawal was observed between
the two groups.
Graft function and acute rejection
As shown in Table 4, biochemical indices of kidney
and pancreatic function were comparable in the
0–3MM and 4–6MM groups during the 3-year
study. However, the rejection-free actuarial survival
rate was signiﬁcantly higher in the 0–3MM group
than in the 4–6MM group (66.4 vs 41.1%, respec-
tively; P¼ 0.003; Figure 1). Cox multivariate regres-
sion analysis showed that the relative risk of rejection
was 2.6 times higher among patients with 4–6 MM
than among those with 0–3 MM (P¼ 0.003).
At the 3-year follow-up, 15 (33%) patients in the
0–3MM group had at least one clinical or biopsy-
proven rejection episode compared with 77 (57%)
patients in the 4–6 MM group (P¼ 0.006). The
difference was also statistically signiﬁcant for biopsy-
proven rejection episodes only (P¼ 0.01). In the
0–3MM group, there were nine biopsy-proven acute
rejection episodes (20%), including three moderate or
severe episodes, compared with 55 episodes (41%) of
biopsy-proven acute rejection in the 4–6MM group,
which included 10 moderate or severe episodes.
Ten (67%) patients in the 0–3 MM group had
a single episode of rejection and ﬁve (33%) had
multiple episodes. This was similar to the experience
in the 4–6 MM group, in which 43 (56%) patients had
a single episode and 34 (44%) had multiple episodes.
Total HLA-DR MM did not appear to inﬂuence
the severity of the ﬁrst biopsy-proven rejection episode.
Among 15 patients with no DR MM, two (13%) had
borderline or mild rejection and two (13%) had
moderate or severe rejection. Among 84 patients
with one DR MM, 23 (27%) had borderline or
mild rejection and four (5%) had moderate or severe
episodes. Similar proportions were found among
81 patients with two DR MM: 26 (32%) had border-
line or mild and seven (9%) had moderate or severe
rejection episodes.
Effect of DR3 and DR4 matching
DR3 or DR4 HLA antigens were found in 171 out
of 187 (91%) transplanted patients; donor HLA
antigens were DR3 or DR4 in 38% (70 out of 182)
of cases. At the 3-year follow-up, there was no signi-
ﬁcant difference in the rate of pancreatic graft loss
among the DR3/4 recipients (32 out of 171; 19%)
and the other DR recipients (three out of 16; 19%).
Among the 180 patients for whom donor–recipient
HLA matching was known, 67 HLA-DR3 or DR4
patients received a HLA-DR3 or DR4 donor organ;
13 of the 67 (19%) patients had lost their pancreas
by 3 years post-transplant. Similarly, in the 113
non-HLA-DR3 or -DR4-matched donor–recipient
patients, 22 (19%) had lost their pancreas by 3 years.
In addition, no statistically signiﬁcant differences
at 1, 2 or 3 years post-transplant were observed in
Table 2. Demographic data and graft characteristics according to
HLA mismatch (MM) in 180 SPK transplant procedures
0–3 MM
(n¼ 45)
4–6 MM
(n¼ 135)
Mean donor age (years) 31.8±9.8 28.5±11.0a
Mean recipient age (years) 40.1±5.2 39.5±7.4
Sex ratio F/M 17/28 48/86
PRA >5% [n (%)] 3 (6.7) 11 (8.1)
Recipient BMI (kg/m2) 23.4±2.7 23.0±3.0
Pancreatic ischaemic time (h:min) 12:21±5:12 10:56±4:58
Kidney ischaemic time (h:min) 13:13±4:58 11:36±4:47a
Pancreatic GVE [n (%)]b 21 (46.7) 70 (51.9)
SPK¼ simultaneous pancreas–kidney; PRA¼ panel-reactive anti-
body; BMI¼body mass index; GVE¼ graft vessel extension.
aP<0.05 vs 0–3 MM.
bGVE is used if the donor vein or artery is too short to be
anastomosed directly to the recipient’s vessel.
Table 3. Inﬂuence of HLA mismatch (MM) on graft and patient
survival following SPK transplantation
Survival (%)
0–3 MM (n¼ 45) 4–6 MM (n¼ 135)
Pancreas
1 year 88.9 80.7
3 years 84.3 76.9
Kidney
1 year 95.6 94.1
3 years 95.6 91.6
Patient
1 year 100 98.5
3 years 97.7 96.2
SPK¼ simultaneous pancreas–kidney; HLA¼ human leukocyte
antigen.
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biochemical indices of kidney and pancreatic func-
tion in organs harvested from DR3/4 donors vs
non-DR3/4 donors (Table 5).
Discussion
The analysis presented here examines the effect of
HLA matching on the outcome of 180 SPK trans-
plantation procedures in a prospective, randomized,
multicentre study primarily designed to compare two
immunosuppressive regimens based on tacrolimus
and cyclosporin-ME. For purposes of comparison,
two unequal groups of patients were analysed, 25%
having 0–3 HLA MM and 75% having 4–6 HLA MM.
With a completed 3-year follow-up for all patients,
there was no evidence to support a beneﬁcial impact
of HLA matching in terms of patient survival, and
pancreatic and kidney graft survival. In addition,
there were no differences between the MM groups
with respect to metabolic function of the transplanted
grafts in terms of creatinine clearance, glycosylated
haemoglobin and fasting blood glucose. There was,
however, a signiﬁcantly lower rate of acute rejection
in the patient group with the superior HLA match.
Although our study showed no impact of this result
on kidney survival, a lower incidence of acute rejec-
tion may be of importance given the relationship
between acute kidney rejection in the ﬁrst year post-
transplant and long-term kidney graft loss [10].
The value of HLA matching in kidney transplanta-
tion and its association with prolonged graft survival
is well recognized [6,7]. Accordingly, most organ-
sharing organizations give priority to kidney recipients
with a high degree of matching. Most studies of HLA
matching in SPK transplantation have looked only
at its effects on pancreas survival, but, in one large
SPK transplantation series from the UNOS registry,
no signiﬁcant beneﬁt of HLA matching on kidney
survival could be established [11]. Despite this,
actuarial kidney graft survival assessed at 8 years post-
transplantation was found to increase in parallel
to the number of overall HLA matches. Statistical
signiﬁcance could not be demonstrated due to the
small number of patients (6%) with an HLA match
>3 [11]. Achieving signiﬁcant differences in graft
survival in our trial may also have been hampered
by a relatively small study population.
The value of HLA matching in pancreas trans-
plantation has evolved over the last 15 years in
parallel with advances in both surgical techniques
and immunosuppression, which have led to improved
clinical outcomes [12,13]. These advances appear to
have masked the potential beneﬁcial effect of HLA
matching in pancreas graft survival. The ﬁrst analysis
of the beneﬁts of HLA matching in pancreas trans-
plantation was published in 1988, using data from the
International Pancreas Transplant Registry (IPTR).
In 380 technically successful cases transplanted between
1966 and 1987, an HLA match of 4 antigens was
associated with a signiﬁcantly higher 1-year pancreas
graft survival than an HLA match 3 (66 vs 54%,
respectively; P¼ 0.038) [14]. The overall 1-year graft
survival rates were 49 and 39%, respectively. Two
single-centre series from the early 1990s (Minneapolis
Table 4. Biochemical indices of kidney and pancreatic graft function according to HLA mismatch (MM) in 180 SPK transplant procedures
0–3MM (n¼ 45) 4–6MM (n¼ 135)
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Creatinine clearance
(ml/min)
65±17 (n¼ 38) 67±18 (n¼ 36) 64±16 (n¼ 34) 67±21 (n¼ 120) 67±22 (n¼ 112) 65±25 (n¼ 91)
Serum creatinine
(mg/dl)
1.4±0.3 (n¼ 38) 1.5±0.5 (n¼ 38) 1.5±0.4 (n¼ 37) 1.4±0.5 (n¼ 120) 1.5±0.7 (n¼ 116) 1.6±0.9 (n¼ 107)
Fasting glucose
(mg/dl)
91±14 (n¼ 33) 89±13 (n¼ 32) 89±17 (n¼ 31) 91±33 (n¼ 99) 90±18 (n¼ 96) 91±33 (n¼ 83)
Fasting C-peptide
(ng/ml)
3.1±1.0 (n¼ 21) 3.3±1.3 (n¼ 21) 3.0±1.5 (n¼ 18) 3.7±2.4 (n¼ 47) 3.5±2.1 (n¼ 47) 2.4±1.4 (n¼ 38)
HbA1C (%) 5.6±0.8 (n¼ 30) 5.3±0.7 (n¼ 31) 5.2±0.8 (n¼ 31) 5.5±1.1 (n¼ 90) 5.4±0.7 (n¼ 97) 5.2±0.7 (n¼ 82)
HLA¼ human leukocyte antigen; SPK¼ simultaneous pancreas–kidney; HbA1c¼ glycosylated haemoglobin.
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Fig. 1. Inﬂuence of HLA mismatch (MM) on rejection-free
survival following simultaneous pancreas–kidney transplantation.
Rejection-free survival was signiﬁcantly higher with 0–3M vs
4–6MM (P¼ 0.003, Kaplan–Meier analysis). ¼ rejection episode;
þ¼ censored.
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and Madison groups) conﬁrmed these observations,
reporting a signiﬁcant impact of HLA-DR match-
ing [15–17]. In addition, a prospective, European
multicentre study (n¼ 62), also from the early 1990s,
reported a beneﬁcial effect of HLA-DR matching,
but not of HLA-A or -B matching, on pancreas
survival, with an overall 1-year graft survival rate of
67% [18]. In contrast, however, an analysis of UNOS
data, which included >3000 transplantations under-
taken in 1988–1994, showed no beneﬁt of HLA
matching on pancreas graft survival, and reported
overall graft survival rates of 85% at 1 year and 75%
at 5 years [11]. Although the issue of small patient
populations remains, no consistent increase in pancreas
graft survival could be related to HLA matching, even
in the relatively large UNOS study [11]. The results
of our own study, in which we achieved a 1-year
pancreas graft survival rate of 83%, concur with the
most recent observations.
The evolution of the impact of HLA matching
on pancreas survival is well illustrated in a second
IPTR study, in which results from the 1987–1994
era were compared with those from the 1995–2000
era [19]. In contrast to the ﬁndings of the European
study, no effect of HLA-DR matching was observed.
However, in the early era (1987–1994), a signiﬁcant
beneﬁcial effect of HLA-A and -B matching was
found for pancreas after kidney (PAK) transplantation
and pancreas transplantation alone (PTA) procedures
as opposed to SPK. This effect persisted in the later
era, but was no longer statistically signiﬁcant because
overall outcomes of pancreas transplantation had
improved markedly [19]. Of note, pancreas survival
has traditionally been less favourable with the PAK
and PTA procedures, primarily due to difﬁculties in
diagnosing rejection, compared with the SPK proce-
dure with which rejection episodes are readily diag-
nosed from kidney biopsies. Despite this, the IPTR
ﬁndings suggest that advances in immunosuppression
have closed the gap in success rates between PTA/PAK
and SPK techniques.
It is important that any discussion on HLAmatching
in SPK transplantation focuses on its feasibility as
well as its beneﬁts. Donor selection criteria for whole-
organ pancreas transplantation are more stringent
than for other abdominal organs. As a result, in the
Eurotransplant and UNOS areas, pancreatic tissue is
procured from only 18–22% of all cadaveric donors
[20,21]. The apparent shortage of available organs
makes it difﬁcult to match for donor and recipient
HLA compatibility. In the UNOS study described
previously [11], fewer than 6% of recipients had a >3
HLA antigen match, while 56% had zero or one
HLA match. One way of overcoming the difﬁculties
in HLA matching of donors with recipients is
to attempt to match HLA cross-reactive groups
(CREGs). These are groups of HLA antigens that
exhibit limited polymorphism and share common
amino acid sequences, enabling them to cross-react
with speciﬁc antibodies. The impact of CREG match-
ing on pancreas graft survival was evaluated in a
recent IPTR registry analysis of 4896 transplants
[22]. Results showed that improved outcome was
only achieved in the PAK and PTA categories. The
impact of CREG matching in kidney transplantation,
however, has been a matter of controversy between
centres in Europe and the USA. North American
registry studies have reported improved outcome,
allocation and reduced HLA sensitization [23,24],
but this has not been the experience in Europe [25].
One possibility is that the regional differences are
related to the higher ethnic disparities in the North
American population.
The current era of highly efﬁcient immunosup-
pressive therapies may have unfolded a shift in the
balance between the beneﬁts and detriments of HLA
matching. Certain HLA antigens, such as DR3 and
DR4, are prevalent in the type 1 diabetic popula-
tion [8]. In our study, 91% of recipients expressed
DR3 or DR4 antigens, compared with 38% of the
donor population. However, there is no evidence
to suggest that a DR3/DR4 pancreas is more likely
to induce recurrence of type 1 diabetes in a patient
receiving immunosuppressive therapy. Accordingly,
we observed no impact of DR3/DR4 matching on
graft survival.
Perhaps more importantly, there is increasing evi-
dence from animal models of autoimmune diabetes
and islet transplantation that b-cell destruction is medi-
ated by MHC-restricted effector mechanisms [26,27].
Table 5. Biochemical indices of kidney and pancreatic graft function according to DR allele
DR3/DR4 donors (n¼ 70) Other DR donors (n¼ 112)
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
Creatinine clearance
(ml/min)
65±19 (n¼ 62) 69±21 (n¼ 53) 65±17 (n¼ 45) 69±21 (n¼ 98) 67±21 (n¼ 97) 65±25 (n¼ 81)
Serum creatinine
(mg/dl)
1.4±0.4 (n¼ 62) 1.4±0.6 (n¼ 56) 1.5±0.7 (n¼ 53) 1.4±0.5 (n¼ 98) 1.5±0.7 (n¼ 100) 1.6±0.9 (n¼ 93)
Fasting glucose
(mg/dl)
94±42 (n¼ 53) 87±12 (n¼ 48) 88±17 (n¼ 41) 89±16 (n¼ 81) 92±19 (n¼ 81) 91±34 (n¼ 75)
Fasting C-peptide
(ng/ml)
3.4±1.6 (n¼ 30) 3.1±1.3 (n¼ 29) 3.0±1.9 (n¼ 21) 3.6±2.4 (n¼ 40) 3.7±2.2 (n¼ 39) 2.4±1.0 (n¼ 35)
HbA1C (%) 5.5±1.3 (n¼ 51) 5.3±0.7 (n¼ 50) 5.2±0.8 (n¼ 43) 5.5±0.7 (n¼ 71) 5.4±0.6 (n¼ 80) 5.2±0.7 (n¼ 72)
SPK¼ simultaneous pancreas–kidney; HbA1c¼ glycosylated haemoglobin.
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In other words, autoantigen presentation might be
more effective in an MHC-matched context. If these
observations apply to the human situation, it may
imply that HLA matching is not desirable for islet or
pancreas transplantation in patients with type 1
diabetes. This may explain why the association between
HLA matching and better kidney survival is not
observed for pancreas survival.
In summary, the current analysis of data from
the Euro-SPK 001 study showed no advantage of
HLA matching in the 3-year patient, kidney graft
and pancreas graft survival rates. A lower rate of
acute kidney rejection was seen when the HLA match
was >3. This observation may have longer-term
implications with respect to improved graft half-
life. However, in the absence of demonstrable beneﬁts
in graft survival, and because of feasibility issues,
HLA matching is currently recommended only for
SPK recipients thought to be at risk of rejection.
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